External environment and oxidation threats DNA most

Recently a study has found that forces from external environment and oxidation may be the greatest threat to an organism's ability to repair damage to its own DNA. The results are published in the journal of the Proceedings of the National Academy of Sciences, which also publishes some other studies on Recombinant protein. The results are based on the first comprehensive, whole genome analysis of spontaneous mutation in the bacterium Escherichia coli.

"Our study investigated 11 DNA repair pathways previously identified as resulting in spontaneous mutations," said Foster, a professor in the IU Bloomington College of Arts and Sciences' Department of Biology. "The striking result was that only loss of the ability to prevent or repair oxidative DNA damage significantly impacted mutation rates. ... All other forms of DNA damage arising within the organism did not disturb the overall accuracy of DNA replication in normally growing cells.

"These results suggest that DNA repair pathways may exist primarily to defend against externally induced damage to the genome," she said. Foster's lab and her work concentrates on DNA mutagenesis and repair. E. coli is a bacterium discovered in mammalian digestive tracts. It's more known as a source of food poisoning. It was chosen for the research because the biological pathways that control DNA repair have changed little as more complex organisms evolved, increasing the chances that the study's results are applicable to higher forms of life, including humans.

Foster's lab created the world's most comprehensive picture of genetic mutation in the species by tracing changes in E. coli's complete genome over the course of 200,000 generations. The IU team concentrated on 11 processes identified in other studies as causing mutation when deactivated, to focus their investigation on the relative importance of the pathways that repair DNA damage to genetic mutation. The pathways were isolated using 11 different strains of E. coli, each defective for one of the specific pathways.

After investigation, the DNA repair pathways under investigation fell into three broad categories. They were the activities of error-prone DNA polymerases, repair of internally induced DNA damage, including oxidation, and repair of DNA damage due to external agents. Each pathway is more or less specific for a given type of DNA damage. External agents such as radiation, chemical compounds and platinum-based compounds, are forces that affect DNA. And internal agents that damage DNA are produced by the body's own normal processes. Oxidation occurs in the body as a result of metabolic processes that use oxygen, creating molecules known as "free radicals" that steal electrons from other molecules in the body, causing damage. Many types of cancer and even aging have been linked to DNA oxidation.

The IU scientists used whole genome sequencing to catalog the specific genetic changes that resulted from loss of each repair pathway. Foster said that, surprisingly, the IU team found that none of the pathways resulted in mutations except the ones that deal with damage from oxidation. This means that the other types of damage—from either internal or external causes—are not a great threat to normally growing cells.

These pathways may be important, however, when cells are exposed to external agents or other forms of stress. The more complete picture of genetic mutation—made possible by the IU team's previous documentation of the bacterium's evolution over 200,000 generations—is likely responsible for the difference in the study's results compared to previous research implicating all 11 DNA repair pathways in genetic mutation, Foster said.

"Previous studies on mutational processes have relied on reporter genes"—single genes that signal larger changes across the genome—"to detect mutations, and these may not be representative of the genome as a whole," she said. "While reporter genes can reveal important mutational processes that occur at particular spots in the DNA, when the whole genome is the target, these localized errors don't appear to contribute to overall mutation."

Foster's next step is investigate DNA repair functions in cells under stress, which may provide a more complete model for mutational processes in living human cells existing in different states and environments all over the body. The experiments and research can help scientists understand more about DNA repair in our body and the importance of them. Flarebio offers good-quality recombinant proteins like recombinant LARGE at good prices.

The risk of cancer can be reduced by gene therapy

Scientists at Washington State University have developed a gene therapy that is expected to reduce the spread of cancer cells. According to the report of International community, gene therapy is a kind of experimental medical technology for the treatment of a variety of genetic diseases. In many experiments, new genes are implanted in the body to help the body fight the disease to replace the damaged genes. According to a study published in the journal Scientific Reports which also publishes other studies on recombinant horse proteins, researchers at Washington State University have changed the way that viruses carry beneficial genes into target cells, thus reducing the risk of cancer-induced blood diseases.

The lead investigator of this study Grant Trobridge and his team are also developing treatments that use stem cells to treat neonatal immunodeficiency, also known as the Boys Bubble Syndrome. He said at a news conference that their goal was to develop a safe and effective therapy for SCID-X1 patients and their families, which is now in the clinical stage.

In the study, Trowbridge and his team used a vector derived from retroviruses, while retroviruses are ideal for gene therapy because they could insert their genes into the maternal genome and are less likely to activate nearby genes that may cause cancer.

The researchers found that after modifying the retrovirus-stem cell interaction method, the fusion degree of it with the surrounding genes was much better than that before the modification. They are convinced that the results of this study will help to achieve more effective gene therapies and they are looking forward to clinical trials within 5 years. Flarebio offer good-quality recombinant proteins like recombinant LARGE at good prices.

Researchers release new method of synthesizing antibody drug coupling

Antibody drug conjugates (ADCs) is a class of drugs that have emerged in recent years. By covalently attaching a small molecule to a specific antibody and using recombinant human proteins, people can target the drug to the target region, thereby increasing the effective concentration of the drug in that region while avoiding the potential side effects of systemic administration.

However, ADC application also has its limitations. One of the biggest challenges is how to use a linker that can both stably attach drug molecules to the antibody and can completely release the drug molecules in the target area in certain circumstances in order to exercise its killing effect. In this process, we may encounter two problems: First, the hydrophilicity of drugs or joint molecules may lead to aggregation of ADC, which greatly affects its stability; the second is whether the effective combination of drug molecules and antibodies stand up.

Recently, scientists from Genentech and WuXi PharmaTech have designed a new linker that contains the p-aminophenyl quaternary ammonium salt (PABQ) component, which can be efficiently conjugated with tertiary amine or heterocyclic nitrogen of the drug molecule Antibody, and it can be released in time to play a pharmacological effects, while because the ammonium salt itself overcomes the hydrophobicity of the charge to overcome the problem. The results are published in the recent issue of the journal Nature. The PABQ linker can be released by proteolytic cleavage or disulfide bond cleavage to release drug molecules to suit different vectors or cell environments.

In the case of the release of drug molecules by proteolytic hydrolysis, the investigators chose a commercially available linker molecule as a starter with a maleimide group that reacts with the thiol group on the antibody molecule linked to the antibody; the ValCit dipeptide contains in the target cells can be protease degraded so that the drug molecules can be released. The bianhydroxyl group in the starting molecule becomes an ideal leaving group after reaction with thionyl chloride and covalently linked to it by reaction with a tertiary amine or heterocyclic nitrogen in the drug molecule. This synthesis method needs no protective groups, thus simplifying the steps, and with thionyl chloride generated by the reaction of intermediates to facilitate separation and purification to facilitate the next step with the drug molecules. The generated ADC thus can be degraded by lysosomes in the target cell, thereby releasing the drug intact.

In the case of disulfide bond cleavage using drug molecules, the pyridine thiol group in the linker molecule is replaced with an antibody molecule that also contains a thiol group, forming an ADC molecule assembled by a disulfide bond. When the ADC enters into the cell, it can react with the widespread existence of intracellular reductant glutathione reaction to break the disulfide bonds, which led to cyclization and 1,6-elimination reaction, finally releasing drug molecules.

The researchers found that the ADC prepared by the above method showed a remarkable killing effect on the human lymphoma and intracellular MRSA in mice, thus showing the potential of drug molecules that are difficult to be applied by ADC technology before.

The new connector technology, developed by GeneTek scientist Dr. Thomas H. Pillow, has greatly expanded the scope of ADC applications and provided valuable new insights into targeted therapy for cancer, bacterial or viral infections. Flarebio offers recombinant proteins of good quality such as recombinant Dpp4 at competitive prices.

A new drug to treat Alzheimer's disease has been developed

Alzheimer's disease has proved promising in a new experimental treatment program, which has no harmful side effects, US researchers reported on Wednesday. The study, published in the journal Science Translational Medicine, based on a small sample of 32 people, led to two broader clinical trials and is currently being studied with more than 3,000 participants. This treatment uses a compound known as verubecestat and was developed by American Pharmaceuticals using recombinant rat proteins. It reduces the level of protein called beta-amyloid by blocking the BACE1 enzyme.

In people with Alzheimer’s disease, protein aggregates form plaques that damage the brain, affecting people & apos; s cognitive abilities, especially memory. The enzyme plays a key role in the production of proteins. 32 patients who participated in the first clinical trial were diagnosed with mild to moderate Alzheimer's disease. Pharmaceutical laboratories are working to develop compounds that prevent or even reverse these plaque formations. The products used to neutralize BACEI enzymes so far have very deleterious side effects, such as liver damage or further neurodegeneration. But, says Matthew Kennedy, Ph.D., of the Merck Research Laboratory in northeastern New Jersey, Verubecestat does not. The researchers found that one or two doses of verubecestat compound sufficient to reduce protein levels without causing side effects.

Two phase III trials are currently underway and will be completed in July 2017 to evaluate the efficacy of verubecestat. If the results are good, the compound can be made into pills within two to three years. According to the forecast, in the United States the baby boomer generation (birth peak) more than 80 years of age, by 2050 suffering from Alzheimer's disease may be more than 28 million people. The World Health Organization says there are 36 million people in the world suffering from some form of dementia, most of them suffering from Alzheimer's disease.

If no effective treatment is available in the next few years, the figure is expected to double by 2030 to over 65.7 million and double again by 2050 if without effective treatment. Flarebio provides good-quality recombinant proteins such as recombinant LARGE at great prices.

Loneliness may be the early symptom of dementia!

Do you often feel lonely? Be careful, this may be the early symptom of dementia! Researchers at Harvard University conducted a survey through recombinant human proteins on 79 adults, 32% of whom had a high level of Alzheimer's disease and the remainder was normal.

The researchers asked everyone to give their own sense of loneliness grade from a minimum of 3 points up to 12 points, hoping to clarify their cerebral cortex amyloid levels and the relationship between loneliness. Amyloid protein accumulation in the brain will form plaques, causing brain cell death, resulting in memory loss and triggering Alzheimer's disease. The researchers found that volunteers had an average score of 5.3, while those with higher levels of amyloid were more likely to feel lonely and that association was also found in those with high levels of apolipoprotein E.

Dr. Nancy Donovan, who led the study, wrote in the Journal of the American Medical Association Psychiatric Volume that the findings will help doctors identify Alzheimer's disease as early as possible. Statistics show that there are currently 47.5 million dementia patients worldwide, of which the most common one is Alzheimer's disease. It is estimated that the proportion of over the age of 65 elderly people suffering from dementia will reach one-third, and the older they are, the higher the proportion is. Dementia can't be cured and the symptoms can only be relieved through medication. Flarebio offers recombinant proteins of good quality such as recombinant Dpp4.

CD98 protein becomes new target of breaking supportive environment of leukemia cells

Acute myelogenous leukemia (AML) is a kind of strong infective cancer caused by abnormality in the process of bone marrow producing blood cells, and it often shows recurrence and drug resistance. Recently, researchers at the University of California, San Diego (UCSD) found that CD98, a cell surface protein expressed by AML cells, plays a role of promoting cancer, whereas CD98 antibody IGN523 is able to arrest AML cancer cells In vitro and in vivo in mice. The results were published in the recent Cell journal Cancer Cell, which also publishes other studies on recombinant mouse proteins.

"In this study, we demonstrated the critical role of CD98 in promoting the growth of AML cancer cells and found that blocking CD98 is effective in preventing cancer cells from gaining nutrients from the surrounding environment," said Professor Tannishtha Reya, author of the article, "This it is expected to inhibit its proliferation and improve the survival rate of patients."

The authors point out that CD98 itself is involved in the proliferation and regeneration of hematopoietic stem cells in bone marrow. In the case of AML, CD98 seems to have become the "accomplice" of cancer. Experiments show that CD98 is necessary for the survival of AML cancer cells. When it was knocked out, the expression of Bcl2L1 and Akt1, which suppress apoptosis in cancer cells, decreased dramatically, while the expression of Casp1, which promotes apoptosis, was up-regulated. Consistent with this, CD98 expression levels in mouse and human leukemic stem cells (LSCs) were significantly higher than in normal hematopoietic stem cells.

In mouse experiments, the role of CD98 in AML is even more prominent. When CD98 was knocked out, the survival rate of AML model mice suddenly increased to nearly 50%, while the knock-out CD98 "suppression" effect even after AML has occurred is still very obvious. Further analysis revealed a significant reduction in the level of leukemic stem cells in the CD98-knockout mice.

Thus, CD98 is a potential therapeutic target of AML. At present, Igenica Biotherapeutics Company is conducting phase 1 clinical trials of anti-CD98 humanized antibody IGN523, and the indications are recurrent or refractory leukemia. The existing results show that IGN523 showed a good safety and preliminary results. In addition, preclinical studies have shown that IGN523 can be significantly amplified in combination with cytarabine, a chemotherapeutic agent, as well as in non-small cell lung cancer and colorectal cancer mouse models.

The anti-cancer effect of IGN523 was also supported in this study. IGN523 was found to significantly inhibit the proliferation of human AML cancer cells in vitro and their interaction with endothelial cells and reduce their carcinogenic capacity in immunodeficient mice.

On the other hand, Professor Tannishtha Reya's team is particularly interested in the potential of IGN523 in childhood leukemia. "Many of the AML mouse models we use are based on mutations that occur in children with leukemia," she says. "Although many pediatric cancers are currently being treated, childhood leukemia continues to have a high rate of relapse. We plan to collaborate with pediatric cancer experts to test whether CD98 blockers can treat childhood leukemia and whether there will be drug resistance and to enhance the anticancer effects of existing therapies." Flarebio provides you with superior recombinant proteins including recombinant TLR2 at competitive prices.

Gene therapy is expected to cure a genetic skin disease causing blisters

The researchers conducted a series of research using recombinant dog proteins and concluded that gene therapy is expected to cure a genetic skin disease, and this skin disease can cause blisters. In an early clinical trial, researchers at Stanford University School of Medicine tested this therapy on four patients with dystrophic dystrophic epidermolysis bullosa.

Researchers said that people with recessive dystrophic bullous epidermolysis can't synthesize proteins that link the upper and lower layers of the skin together. Even with small frictions, these cortices slide and produce blisters. In the worst case, the patient would die in infancy.

In this study, researchers transplants patients' own hereditary correct skin graft to the wound caused by skin disease. Transplanted skin can promote wound healing, and it is well-tolerated.

"Our Phase I clinical trials show that this therapy is safe and we are fortunate to see some good clinical results," said Dr. Jean Tang, associate professor of dermatology. In some cases, some wounds that had not healed for 5 years have been successfully treated using gene therapy. For patients, it means a substantial increase in quality of life.

The next step is to evaluate the effect of this therapy on patients older than 13 years. If it can treat children, then it can be used to prevent serious chronic wounds and scar formation. However, more trials are needed to make this therapy a widely-accepted clinical routine therapy. The study has been published in the journal American Medical Association on November 1. Flarebio offers good-quality recombinant proteins like recombinant TLR2 at competitive prices.